(Q24241300)

PubMed publication ID

18843646

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18843646%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

0 references

1 reference

title

Fluticasone at different doses for chronic asthma in adults and children (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6984662&resulttype=core&format=json

14 May 2020

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6984662&resulttype=core&format=json

14 May 2020

Christopher Cates

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6984662&resulttype=core&format=json

14 May 2020

author name string

Nick P Adams

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6984662&resulttype=core&format=json

14 May 2020

Paul Jones

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6984662&resulttype=core&format=json

14 May 2020

Toby J Lasserson

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6984662&resulttype=core&format=json

14 May 2020

Benedict Griffiths

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6984662&resulttype=core&format=json

14 May 2020

publication date

8 October 2008

1 reference

PubMed publication ID

18843646

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18843646%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

15 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6984662&resulttype=core&format=json

14 May 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6984662&resulttype=core&format=json

14 May 2020

page(s)

CD003534

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6984662&resulttype=core&format=json

The effect of fluticasone propionate on functional status and sleep in children with asthma and on the quality of life of their parents.

14 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003534.PUB3

Suppression of hypothalamic-pituitary-adrenal axis activity with inhaled flunisolide and fluticasone propionate in adult asthma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003534.PUB3

Vascular component of airway remodeling in asthma is reduced by high dose of fluticasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003534.PUB3

A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. International Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003534.PUB3

Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003534.PUB3

Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5'monophosphate in asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003534.PUB3

Fluticasone propionate compared with theophylline for mild-to-moderate asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003534.PUB3

Low- and high-dose fluticasone propionate in asthma; effects during and after treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003534.PUB3

Fifty μg b.i.d. of inhaled fluticasone propionate (FP) are effective in stable asthmatics previously treated with a higher dose of FP

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003534.PUB3

Addition of salmeterol to fluticasone propionate treatment in moderate-to-severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003534.PUB3

Potential effects of fluticasone propionate on bone mineral density in patients with asthma: a 2-year randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003534.PUB3

Effects of fluticasone propionate, triamcinolone acetonide, prednisone, and placebo on the hypothalamic-pituitary-adrenal axis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003534.PUB3

Fluticasone propionate hydrofluoroalkane inhalation aerosol in patients receiving inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003534.PUB3

Effects of inhaled fluticasone and oral prednisolone on clinical and inflammatory parameters in patients with asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003534.PUB3

Fluticasone propionate powder: oral corticosteroid-sparing effect and improved lung function and quality of life in patients with severe chronic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003534.PUB3

Fluticasone propionate results in improved glucocorticoid receptor binding affinity and reduced oral glucocorticoid requirements in severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003534.PUB3

Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003534.PUB3

Fluticasone propionate improves quality of life in patients with asthma requiring oral corticosteroids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003534.PUB3

Effects of varying doses of fluticasone propionate on the physiology and bronchial wall immunopathology in mild-to-moderate asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003534.PUB3

Impact of fluticasone propionate powder on health-related quality of life in patients with moderate asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003534.PUB3

Inhaled fluticasone propionate delivered by means of two different multidose powder inhalers is effective and safe in a large pediatric population with persistent asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003534.PUB3

Fluticasone propionate HFA-134a pressurized metered-dose inhaler in adolescents and adults with moderate to severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003534.PUB3

Effects of the inhaled corticosteroids fluticasone propionate, triamcinolone acetonide, and flunisolide and oral prednisone on the hypothalamic-pituitary-adrenal axis in adult patients with asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003534.PUB3

Fluticasone propionate in asthma: a long term dose comparison study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003534.PUB3

Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003534.PUB3

A 12-week dose-ranging study of fluticasone propionate powder in the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003534.PUB3

Effectiveness of fluticasone propionate in patients with moderate asthma: a dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003534.PUB3

Therapeutic ratio of hydrofluoroalkane and chlorofluorocarbon formulations of fluticasone propionate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003534.PUB3

Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003534.PUB3

Adrenocortical activity with repeated twice daily dosing of fluticasone propionate and budesonide given via a large volume spacer to asthmatic school children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003534.PUB3

Effect of one year treatment with inhaled fluticasone propionate or beclomethasone dipropionate on bone density and bone metabolism: a randomised parallel group study in adult asthmatic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003534.PUB3

One-year treatment with different dosing schedules of fluticasone propionate in childhood asthma. Effects on hyperresponsiveness, lung function, and height

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003534.PUB3

Long-term efficacy and safety of fluticasone propionate powder administered once or twice daily via inhaler to patients with moderate asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003534.PUB3

Regular treatment with salmeterol for chronic asthma: serious adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003534.PUB3

Systematic Reviews in Health Care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003534.PUB3

Safety of inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003534.PUB3

The Effect of Inhaled Fluticasone Propionate in the Treatment of Young Asthmatic Children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003534.PUB3

Fluticasone propionate aerosol: efficacy in patients with mild to moderate asthma. Fluticasone Propionate Asthma Study Group

21 January 2018

1 reference

12 December 2020

Dose-responses over time to inhaled fluticasone propionate treatment of exercise- and methacholine-induced bronchoconstriction in children with asthma

1 reference

12 December 2020

1 reference

12 December 2020

A study on the clinical equivalence and patient preference of fluticasone propionate 250 microg twice daily via the Diskus/Accuhaler inhaler or the Diskhaler inhaler in adult asthmatic patients

1 reference

12 December 2020

Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma

1 reference

12 December 2020

Evaluation of fluticasone propionate (500 micrograms day-1) administered either as dry powder via a Diskhaler inhaler or pressurized inhaler and compared with beclomethasone dipropionate (1000 micrograms day-1) administered by pressurized inhaler

1 reference

12 December 2020

Fluticasone propionate 50 micrograms BID versus 100 micrograms BID in the treatment of children with persistent asthma. Fluticasone Propionate Study Group

1 reference

12 December 2020

Comparison of once- and twice-daily dosing of fluticasone propionate 200 micrograms per day administered by diskus device in patients with asthma treated with or without inhaled corticosteroids

1 reference

12 December 2020

Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in patients with mild-to-moderate asthma

1 reference

12 December 2020

Efficacy of inhaled fluticasone propionate in asthma results from topical and not from systemic activity.

1 reference

12 December 2020

Growth in asthmatic children treated with fluticasone propionate. Fluticasone Propionate Asthma Study Group

1 reference

12 December 2020

Hydrofluoroalkane-134a beclomethasone dipropionate, 400 microg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 microg, for the treatment of moderate asthma

1 reference

12 December 2020

Fluticasone versus placebo for chronic asthma in adults and children

1 reference

12 December 2020

British guideline on the management of asthma

1 reference

12 December 2020

Efficacy and safety of dry powder fluticasone propionate in children with persistent asthma

1 reference

12 December 2020

Importance of selected inhaler characteristics and acceptance of a new breath-actuated powder inhalation device

1 reference

12 December 2020

A comparison of multiple doses of fluticasone propionate and beclomethasone dipropionate in subjects with persistent asthma

1 reference

12 December 2020

Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. U.K. study group

1 reference

12 December 2020

Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma

1 reference

12 December 2020

Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. The Fluticasone Propionate Asthma Study Group

1 reference

12 December 2020

High dose fluticasone propionate, 1 mg daily, versus fluticasone propionate, 2 mg daily, or budesonide, 1.6 mg daily, in patients with chronic severe asthma. International Study Group

1 reference

12 December 2020

Short-term knemometry and urine cortisol excretion in children treated with fluticasone propionate and budesonide: a dose response study

1 reference

12 December 2020

A dose-ranging study of fluticasone propionate administered once daily via multidose powder inhaler to patients with moderate asthma

1 reference

12 December 2020

10.1002/14651858.CD003534.PUB3

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

2142810

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6984662&resulttype=core&format=json

14 May 2020

2142810

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6984662&resulttype=core&format=json

14 May 2020

PubMed publication ID

18843646

2 references

Consolidated OpenCitations Corpus – April 2017

2142810